TaoWeave (NASDAQ:TWAV – Get Free Report) and Hyperion DeFi (NASDAQ:HYPD – Get Free Report) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.
Institutional & Insider Ownership
2.0% of TaoWeave shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 2.7% of TaoWeave shares are owned by insiders. Comparatively, 7.5% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares TaoWeave and Hyperion DeFi”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TaoWeave | $2.44 million | 2.23 | -$6.36 million | ($1.60) | -0.87 |
| Hyperion DeFi | $810,000.00 | 63.31 | -$45.31 million | ($6.53) | -0.51 |
TaoWeave has higher revenue and earnings than Hyperion DeFi. TaoWeave is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for TaoWeave and Hyperion DeFi, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TaoWeave | 1 | 0 | 0 | 0 | 1.00 |
| Hyperion DeFi | 2 | 0 | 2 | 0 | 2.00 |
Hyperion DeFi has a consensus price target of $7.20, suggesting a potential upside of 118.18%. Given Hyperion DeFi’s stronger consensus rating and higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than TaoWeave.
Profitability
This table compares TaoWeave and Hyperion DeFi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TaoWeave | -272.06% | -108.74% | -94.22% |
| Hyperion DeFi | 416.56% | -11.62% | -9.96% |
Risk and Volatility
TaoWeave has a beta of 2.55, suggesting that its stock price is 155% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.
Summary
Hyperion DeFi beats TaoWeave on 10 of the 14 factors compared between the two stocks.
About TaoWeave
Oblong Inc., together with its subsidiaries, provides multi-stream collaboration technologies and managed services for video collaboration and network applications in the United States and internationally. The company operates in two segments, Collaboration Products and Managed Services. Its flagship product is Mezzanine that enables visual collaboration across multi-users, multi-screens, multi-devices, and multi-locations for video telepresence, laptop and application sharing, and whiteboard sharing and slides applications. The company also provides managed videoconferencing services; and remote service management, which provides an overlay to enterprise information technology and channel partner support organizations, as well as support and management services for customer video environments. In addition, it offers network services comprising Cloud Connect: Video that allows its customers to outsource the management of their video traffic to them and provides the customer’s office locations with a secure, dedicated video network connection to the Oblong Cloud for video communications; Cloud Connect: Converge, which offers customized multiprotocol label switching solutions; and Cloud Connect: Cross Connect that allows the customer to leverage existing carrier for the extension of a Layer 2 private line to its data center. Further, it provides professional services, such as software development, visual and interaction design, engineering, and project support services; and resells video equipment to its customers. Oblong Inc. is based in Conifer, Colorado.
About Hyperion DeFi
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Receive News & Ratings for TaoWeave Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TaoWeave and related companies with MarketBeat.com's FREE daily email newsletter.
